Literature DB >> 19100374

The role of macrophages in xenograft rejection.

A Cadili1, N Kneteman.   

Abstract

Safe and effective xenotransplantation would provide a valuable answer to many of the limitations of allogenic transplantation. Such limitations include scarcity of organ supply and morbidity to donors in cases of living-related donor transplantation. The main hurdle to the efficacious application of xenotransplantation in clinical medicine is the fierce host immune response to xenografts. This immune response is embodied in 3 different types of xenograft rejection. Both hyperacute rejection and delayed xenograft rejection are mediated by natural antibodies and are concerned primarily with whole organ rejection. Cellular xenograft rejection (CXR), on the other hand, is concerned with both whole organ and CXR and is mediated by innate immunity rather than natural antibodies. Macrophages, which are cells of the innate immune system, play a role in all 3 types of xenograft rejection (not just CXR). They impart their effects both directly and through T-cell activation.

Entities:  

Mesh:

Year:  2008        PMID: 19100374     DOI: 10.1016/j.transproceed.2008.08.125

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  11 in total

1.  Human CD200 suppresses macrophage-mediated xenogeneic cytotoxicity and phagocytosis.

Authors:  Rieko Sakai; Akira Maeda; Thuy-Vy Choi; Pei-Chi Lo; Patmika Jiaravuthisan; Afifah Mod Shabri; Han-Tang Wang; Rei Matsuura; Tasuku Kodama; Hiroshi Eguchi; Hiroomi Okuyama; Shuji Miyagawa
Journal:  Surg Today       Date:  2017-06-01       Impact factor: 2.549

2.  Suppression of xenogeneic innate immune response by a membrane-type human surfactant protein-A.

Authors:  Chiyoshi Toyama; Akira Maeda; Shuhei Kogata; Riho Yamamoto; Kazunori Masahata; Takehisa Ueno; Masafumi Kamiyama; Yuko Tazuke; Hiroshi Eguchi; Hiroomi Okuyama; Shuji Miyagawa
Journal:  Exp Ther Med       Date:  2022-07-26       Impact factor: 2.751

3.  Comparison of immunopathology and locomotor recovery in C57BL/6, BUB/BnJ, and NOD-SCID mice after contusion spinal cord injury.

Authors:  Sabina Luchetti; Kevin D Beck; Manuel D Galvan; Richard Silva; Brian J Cummings; Aileen J Anderson
Journal:  J Neurotrauma       Date:  2010-02       Impact factor: 5.269

Review 4.  Cardiac xenotransplantation: a promising way to treat advanced heart failure.

Authors:  Songren Shu; Jie Ren; Jiangping Song
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

5.  Analysis of innate defences against Plasmodium falciparum in immunodeficient mice.

Authors:  Ludovic Arnold; Rajeev Kumar Tyagi; Pedro Mejia; Nico Van Rooijen; Jean-Louis Pérignon; Pierre Druilhe
Journal:  Malar J       Date:  2010-07-09       Impact factor: 2.979

Review 6.  Xenotransplantation: Current Status in Preclinical Research.

Authors:  Tianyu Lu; Bochao Yang; Ruolin Wang; Chuan Qin
Journal:  Front Immunol       Date:  2020-01-23       Impact factor: 7.561

7.  The Potential Role of Human NME1 in Neuronal Differentiation of Porcine Mesenchymal Stem Cells: Application of NB-hNME1 as a Human NME1 Suppressor.

Authors:  Jin Hyoung Cho; Won Seok Ju; Sang Young Seo; Bo Hyun Kim; Ji-Su Kim; Jong-Geol Kim; Soon Ju Park; Young-Kug Choo
Journal:  Int J Mol Sci       Date:  2021-11-11       Impact factor: 5.923

Review 8.  Current status of xenotransplantation research and the strategies for preventing xenograft rejection.

Authors:  Qiao Zhou; Ting Li; Kaiwen Wang; Qi Zhang; Zhuowen Geng; Shaoping Deng; Chunming Cheng; Yi Wang
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

9.  Roles of microglia/macrophage and antibody in cell sheet transplantation in the central nervous system.

Authors:  Naoto Honda; Yasuhiro Watanabe; Yuta Tokuoka; Ritsuko Hanajima
Journal:  Stem Cell Res Ther       Date:  2022-09-11       Impact factor: 8.079

10.  Immuno-regulatory function of indoleamine 2,3 dioxygenase through modulation of innate immune responses.

Authors:  Malihe-Sadat Poormasjedi-Meibod; Raza B Jalili; Azadeh Hosseini-Tabatabaei; Ryan Hartwell; Aziz Ghahary
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.